[HTML][HTML] Incidental detection of lung adenocarcinoma presenting as an anterior mediastinal mass on 18F-fluciclovine PET/CT in a patient with primary prostate cancer.
OA Abiodun-Ojo, AA Akintayo, GL Sica… - Clinical nuclear …, 2020 - ncbi.nlm.nih.gov
Clinical nuclear medicine, 2020•ncbi.nlm.nih.gov
Abstract 18 F-fluciclovine is a positron emission tomography (PET) radiotracer approved for
detection of recurrent prostate cancer, with utility in other malignancies being investigated.
We present a case of a 71-year-old man with high-risk primary prostate cancer (Gleason
score 9; prostate-specific antigen 34 ng/ml) and newly diagnosed lung adenocarcinoma. As
part of a clinical trial (NCT03081884
detection of recurrent prostate cancer, with utility in other malignancies being investigated.
We present a case of a 71-year-old man with high-risk primary prostate cancer (Gleason
score 9; prostate-specific antigen 34 ng/ml) and newly diagnosed lung adenocarcinoma. As
part of a clinical trial (NCT03081884
Abstract
18 F-fluciclovine is a positron emission tomography (PET) radiotracer approved for detection of recurrent prostate cancer, with utility in other malignancies being investigated. We present a case of a 71-year-old man with high-risk primary prostate cancer (Gleason score 9; prostate-specific antigen 34 ng/ml) and newly diagnosed lung adenocarcinoma. As part of a clinical trial (NCT03081884
ncbi.nlm.nih.gov
